PharmaCyte Biotech shares surge 10.10% intraday as Phase 2b pancreatic cancer trials advance.

PharmaCyte Biotech surged 10.10% intraday following news of pivotal Phase 2b trials for its Cell-in-a-Box® pancreatic cancer therapy. The company highlighted progress in preparing clinical trials targeting locally advanced pancreatic cancer, a high-mortality disease, with a focus on improving survival rates via targeted chemotherapy delivery. Strategic collaborations with research institutions and regulatory engagement further underscore its potential to advance therapies to market. The announcement aligns with the stock’s upward movement, reflecting optimism around the technology’s clinical and commercial prospects.